Back to News
Market Impact: 0.3
BridgeBio Pharma's Oral Infigratinib Gains FDA Filing Acceptance For Achondroplasia NDA
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
The FDA accepted BridgeBio Pharma’s New Drug Application for oral infigratinib with Priority Review, for treating children with achondroplasia. The filing acceptance is a positive regulatory milestone; the article excerpt provides no review decision date or clinical and financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BBIO0.75
More News
- William Blair reiterates Outperform on BridgeBio Pharma stock
- Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
- Australia top court rules against coal mine expansion, citing climate harm
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Paramount's hard-fought takeover of Warner Bros. Discovery closes Tuesday. Here's how we got here